NEWS & PRESS

Nucleix Receives Reimbursement for Bladder EpiCheck® in the Netherlands

Nucleix Receives Reimbursement for Bladder EpiCheck® in the Netherlands

06/11/2023
SAN DIEGO & REHOVOT, Israel--(BUSINESS WIRE)--Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced...
Nucleix Bladder EpiCheck® Now Available in France via the Association Francaise d'Urologie (AFU) Registry for Surveillance of Recurrence of Bladder Cancer

Nucleix Bladder EpiCheck® Now Available in France via the Association Francaise d'Urologie (AFU) Registry for Surveillance of Recurrence of Bladder Cancer

23/10/2023
SAN DIEGO & REHOVOT, Israel--(BUSINESS WIRE)--Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced...
Nucleix Advances Early Lung Cancer Detection Program with Promising Performance Data and Appointment of Chief Scientific Officer

Nucleix Advances Early Lung Cancer Detection Program with Promising Performance Data and Appointment of Chief Scientific Officer

11/10/2023
SAN DIEGO & REHOVOT, Israel--(BUSINESS WIRE)--Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced...
Nucleix Announces Upcoming Presentation of Performance Data from Sightline Study of Lung EpiCheck® at the American College of Chest Physicians (CHEST) 2023 Annual Meeting

Nucleix Announces Upcoming Presentation of Performance Data from Sightline Study of Lung EpiCheck® at the American College of Chest Physicians (CHEST) 2023 Annual Meeting

02/10/2023
SAN DIEGO & REHOVOT, Israel--(BUSINESS WIRE)--Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced...
Nucleix Appoints Michael G. Vicari as Chief Commercial Officer Mr. Vicari to plan and lead the company’s commercialization of Lung EpiCheck®

Nucleix Appoints Michael G. Vicari as Chief Commercial Officer Mr. Vicari to plan and lead the company’s commercialization of Lung EpiCheck®

06/06/2023
SAN DIEGO & REHOVOT, Israel--(BUSINESS WIRE)--Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, announced the...

STAY UPDATED ON THE LATEST NEWS FROM NUCLEIX!

Subscribe to one of our social media channels

close

Subscription Confirmation Required

Go to your email inbox

Go to your email inbox

Go to the inbox of the email
address you just used to sign up.

Open the confirmation email

Open the confirmation email

Find the email sent by us. It has the subject line
“Nucleix: Please Confirm Subscription” and I
sent from “info@nucleix.com”.

Click the confirmation link

Click the confirmation link

Click on the link inside the <br>email and you’re good to go.

GOT IT !